<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03890406</url>
  </required_header>
  <id_info>
    <org_study_id>DEEPTIVA</org_study_id>
    <nct_id>NCT03890406</nct_id>
  </id_info>
  <brief_title>The Effect of Deep Neuromuscular Blockade on Requirement of Intravenous Anesthetic Agent</brief_title>
  <official_title>The Effect of Deep Neuromuscular Blockade on Requirement of Intravenous Anesthetic Agent During Laparoscopic Colorectal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, deep neuromuscular blockade during general anesthesia has been studied by many&#xD;
      authors regarding various effects upon patients' outcomes and surgical conditions. We believe&#xD;
      deep neuromuscular blockade can be especially beneficial in laparoscopic surgery, because it&#xD;
      can expand surgical space and prevent patients' minute movements that can disturb precise&#xD;
      operations. In clinical situations, anesthetists tend to compensate the insufficiency of&#xD;
      neuromuscular blockade by increasing the dose of other anesthetic agents, which can prolong&#xD;
      patients' recovery time and impair the surgical condition. In this study, we plan to divide&#xD;
      the patients into 2 groups according to the depth of neuromuscular blockade, and compare the&#xD;
      dose of anesthetic agent used to maintain surgical condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing elective laparoscopic colorectal surgery are going to be recruited and&#xD;
      divided into 2 groups: Group D will receive deep neuromuscular blockade, and Group M will&#xD;
      receive moderate neuromuscular blockade using continuous infusion of rocuronium.&#xD;
      Acceleromyography(TOF-watch SX) will be used to monitor the depth of blockade. In both&#xD;
      groups, the anesthesia will be maintained with TIVA(total intra-venous anesthesia) including&#xD;
      continuous target-controlled infusion of propofol and remifentanil. During the surgery, the&#xD;
      number of patient movement and restoration of self respiration will be recorded. At the end&#xD;
      of anesthesia, the dose of propofol and remifentanil used will be assessed and compared&#xD;
      between the groups. Also, the satisfaction score of surgeons regarding the surgical&#xD;
      condition, the anesthesia time, the operation time will be documented. After the patients are&#xD;
      discharged, their charts are going to be reviewed and whether any pulmonary or surgical&#xD;
      complications occurred will be documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of propofol</measure>
    <time_frame>intraoperative (from starting of anesthesia to end of anesthesia)</time_frame>
    <description>the amount of propofol used (mg/kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosage of remifentanil</measure>
    <time_frame>intraoperative (from starting of anesthesia to end of anesthesia)</time_frame>
    <description>the amount of remifentanil used (mcg/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient movement</measure>
    <time_frame>intraoperative (from tracheal intubation to injection of neuromuscular reversal agent)</time_frame>
    <description>the observed number of patient movement during the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient self respiration</measure>
    <time_frame>intraoperative (from tracheal intubation to injection of neuromuscular reversal agent)</time_frame>
    <description>the observed number of restoration of self breathing during the surgery (ex. EtCO2 notching)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical condition score</measure>
    <time_frame>assessed at the end of the surgery</time_frame>
    <description>the 5-point satisfaction score of surgeon regarding surgical conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Laparoscopy</condition>
  <condition>General Anesthesia</condition>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deep neuromuscular blockade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderate neuromuscular blockade</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium: PTC(Post-tetanic count) 1~2</intervention_name>
    <description>Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Deep block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium: TOF(Train-of-four) 1~2</intervention_name>
    <description>Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.</description>
    <arm_group_label>Group M</arm_group_label>
    <other_name>Moderate block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing elective laparoscopic colorectal resection due to benign or&#xD;
             malignant neoplasm of colon or rectum&#xD;
&#xD;
          -  ASA class I or II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving medications known to have drug-drug interaction with neuromuscular&#xD;
             blocking agents&#xD;
&#xD;
          -  Patients who have significantly impaired cardiac, pulmonary, hepatic, renal function&#xD;
&#xD;
          -  Patients who are pregnant&#xD;
&#xD;
          -  Patients who are known to have hypersensitivity to the&#xD;
             anesthetic/analgesic/neuromuscular blocking agents which are going to be used in the&#xD;
             study&#xD;
&#xD;
          -  BMI &lt; 18.5 or &gt; 35.0 kg/m2&#xD;
&#xD;
          -  Patients with previous history of open abdominal surgery&#xD;
&#xD;
          -  Patients with previous history of malignant hyperthermia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ah Young Oh, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>BON WOOK KOO</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Deep neuromuscular blockade</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

